26.61
-0.63 (-2.31%)
Previous Close | 27.24 |
Open | 26.34 |
Volume | 699,446 |
Avg. Volume (3M) | 591,123 |
Market Cap | 1,267,969,152 |
Price / Earnings (TTM) | 8.70 |
Price / Sales | 1.66 |
Price / Book | 1.51 |
52 Weeks Range | |
Earnings Date | 6 May 2025 - 12 May 2025 |
Profit Margin | 21.79% |
Operating Margin (TTM) | 24.20% |
Diluted EPS (TTM) | 3.06 |
Quarterly Revenue Growth (YOY) | 4.70% |
Quarterly Earnings Growth (YOY) | 5.00% |
Total Debt/Equity (MRQ) | 88.84% |
Current Ratio (MRQ) | 3.07 |
Operating Cash Flow (TTM) | 213.39 M |
Levered Free Cash Flow (TTM) | 18.89 M |
Return on Assets (TTM) | 8.31% |
Return on Equity (TTM) | 23.26% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
Stock | Amphastar Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | -0.5 |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -2.5 |
Average | 1.00 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Insiders | 23.01% |
% Held by Institutions | 76.19% |
52 Weeks Range | ||
Median | 32.00 (20.26%) | |
Total | 1 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Piper Sandler | 21 Mar 2025 | 32.00 (20.26%) | Hold | 28.29 |
04 Feb 2025 | 36.00 (35.29%) | Hold | 33.19 |
No data within this time range.
Date | Type | Details |
---|---|---|
03 Apr 2025 | Announcement | Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
28 Mar 2025 | Announcement | International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award |
05 Mar 2025 | Announcement | Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference |
27 Feb 2025 | Announcement | Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024 |
20 Feb 2025 | Announcement | Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |